
    
      The study aims to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in
      the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.
    
  